DAWN 15.08 Day One Biopharmaceuticals, Inc.
| Range: | 9.67-18.07 | Vol Avg: | 989085 | Last Div: | 0 | Changes: | 0.35 |
| Beta: | -1.52 | Cap: | 1.22B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu May 27 2021 | Empoloyees: | 169 | ||
| CUSIP: | 23954D109 | CIK: | 0001845337 | ISIN: | US23954D1090 | Country: | US |
| CEO: | Dr. Jeremy Bender M.B.A., Ph.D. | Website: | https://dayonebio.com | ||||
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Stock Details
DAWN 24
Day One Biopharmaceuticals upgraded to Buy from Underperform at BofA
Alec Stranahan·Thu Aug 01 2024
Bank of America Securities
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow